Michael Raymond Berger

Address:

6220 Winters Rdg, Hanover, MD 21076

Phone:

(443)2967823

VIN:

5FNRL38797B055835

Make:

HONDA

Model:

ODYSSEY

Year:

2007

US Patent:

20220192435, Jun 23, 2022

Filed:

Sep 2, 2021

Appl. No.:

17/465164

Inventors:

- Cincinnati OH, US
Megan Kathryn Helms - Hamilton OH, US
David Steven Mesko - Wyoming OH, US
Michael E. Berger - Brooklyn NY, US
Adem Önalan - Jersey City NJ, US
Marco C. Perry - Brooklyn NY, US

International Classification:

A47K 5/12

Abstract:

A liquid dispenser includes of a bottle for housing the liquid, a pumping mechanism for discharging liquid from the bottle, and a boss that is connected to and extends from the bottom of the bottle. The boss on the bottle mates with a socket in a base to selectively secure the bottle to the base and a countertop or wall mounted support. The boss and socket are shaped so as to allow for a single orientation of the bottle. The combination of the boss on the bottle and the socket in the base provides a liquid soap dispensing apparatus having a counter-top mounting system that makes it possible to securely anchor the liquid dispensing device to a surface such as a counter-top and still allow easy removal for portability, so the dispenser can be transported and used in other areas. The apparatus also allows the soap reservoir to be easily refilled and utilizes readily available pump components.

US Patent:

20190309371, Oct 10, 2019

Filed:

Jan 1, 2019

Appl. No.:

16/237692

Inventors:

- New York NY, US
Michael F. Berger - New York NY, US
Robert A. Soslow - New York NY, US
Petar Jelinic - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

C12Q 1/6886
A61K 31/7088

Abstract:

Provided are compositions and methods for the identification and treatment of ovarian cancers, such as small cell ovarian cancers, in particular small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), which ovarian cancers are characterized by reduced SMARCA4 gene expression and/or protein function and, as a consequence, are sensitive to growth and/or survival inhibition by one or more compounds that restore SMARCA4 gene expression and/or protein function.

US Patent:

20160326596, Nov 10, 2016

Filed:

Dec 31, 2014

Appl. No.:

15/109403

Inventors:

- New York NY, US
Michael F. Berger - New York NY, US
Robert A. Soslow - New York NY, US
Petar Jelinic - New York NY, US

International Classification:

C12Q 1/68

Abstract:

Provided are compositions and methods for the identification and treatment of ovarian cancers, such as small cell ovarian cancers, in particular small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), which ovarian cancers are characterized by reduced SMARCA4 gene expression and/or protein function and, as a consequence, are sensitive to growth and/or survival inhibition by one or more compounds that restore SMARCA4 gene expression and/or protein function.

US Patent:

20160067229, Mar 10, 2016

Filed:

Sep 14, 2015

Appl. No.:

14/853468

Inventors:

- New York NY, US
Michael Berger - New York NY, US
Robert Motzer - Ridgewood NJ, US
Martin H. Voss - New York NY, US
Ari A. Hakimi - New Rochelle NY, US
Can Pham - New York NY, US
Emily Cheng - Englewood Cliffs NJ, US
Rose Brannon - Cambridge MA, US
Jianing Xu - Bronx NY, US

International Classification:

A61K 31/436
C12Q 1/68

Abstract:

The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a rapamycin analog would produce an anti-cancer effect in a subject. It is based, at least in part, on the results of experiments employing an integrated next-generation sequencing approach to interrogate spatially separated tumor specimens from the same individuals to decipher intra-tumor and intertumor heterogeneity and determine the oncogenomic basis of exceptional therapeutic benefit to rapalogs in kidney cancer patients. These experiments implicated loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR in therapeutic responsiveness to rapamycin analogs. Accordingly, in non-limiting embodiments, the present invention provides for assay methods and kits for determining the presence of loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR, and methods of using such determinations in selecting a therapeutic regimen for a cancer patient and in methods of treating cancer patients. In particular non-limiting embodiments, a plurality of tumor sites are evaluated and the composite effect of the genetic background on mTOR function is assessed.